

## **Change of Company Address**

**27 April 2021**

**Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF)**, advises that, effective 27 April 2021, the Company's address details will change to the following:

**Registered Office & Principal Place of Business**

Level 3  
101 St Georges Terrace  
PERTH WA 6000

The following details will remain the same:

**Postal Address**

GPO Box 5457  
PERTH WA 6831

Telephone: 08 6558 0886  
Fax: 08 6316 3337

This announcement has been approved and authorised for release by the board of Zelira Therapeutics Limited.

**Osagie Imasogie**

**Chairman**

**For further information please contact:**

**Company**

Dr Oludare Odumosu  
Managing Director & CEO  
+1 909 855 0675  
oodumosu@zeliratx.com

**Investors**

Market Eye Pty Ltd  
ABN 54 137 305 527  
Melbourne | Sydney  
T: +61 3 9591 8900  
F: +61 3 9591 8999  
W: [www.marketeye.com.au](http://www.marketeye.com.au)

**About Zelira Therapeutics ([www.zeliratx.com](http://www.zeliratx.com))**

**Australia**

Level 3  
101 St Georges Terrace  
Perth WA 6000  
AUSTRALIA  
Tel: +61 8 6558 0886  
Fax: +61 8 6316 3337  
E: [enquiries@zeliratx.com](mailto:enquiries@zeliratx.com)  
W: [www.zeliratx.com](http://www.zeliratx.com)  
ACN 103 782 378

**USA**

5110 Campus Drive  
Suite 150  
Plymouth Meeting, PA  
19462  
UNITED STATES OF AMERICA  
Tel: +1 484-630-0650

Zelira Therapeutics Ltd is a leading global therapeutic medical cannabis company with access to the world's largest and fastest growing cannabis markets. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets. The Company is focused on developing branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its Rx business, including insomnia, autism and chronic non-cancer pain.

The Company has two proprietary formulations under the HOPE™ brand that are generating revenues in Australia, Pennsylvania and have been licensed in Louisiana and Washington D.C. with other states in the US expected to follow. Zelira is also generating revenue in Australia from its proprietary and patented Zenivol™ - a leading cannabinoid-based medicine for treatment of chronic insomnia. Zenivol™ has successfully completed the world's first Phase 1b clinical trial for chronic insomnia where it was found to be a safe and effective treatment. In 2020, Zelira partnered with SprinJene®Natural to develop and commercialise natural and organic oral care products under the SprinjeneCBD brand, as part of Zelira's OTC business. The SprinjeneCBD toothpaste product is the first of several scientifically formulated, hemp-derived, oral care products containing cannabinoids and based on the propriety and patented technology of Blackseed oil and Zinc.

The Company conducts its work in partnership with world-leading researchers and organizations including Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States.